Insomnia Market Report 2026

Insomnia Market Overview

• Insomnia market size has reached to $5.22 billion in 2025 • Expected to grow to $7.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.3% • Growth Driver: Rising Prevalence Of Chronic Diseases To Drive Market Growth • Market Trend: Innovative Insomnia Drugs Reshaping The Market • North America was the largest region in 2025.

What Is Covered Under Insomnia Market?

Insomnia is a sleep disorder in which the patient has trouble falling or staying asleep. Depending on the duration, the condition is either short-term (acute) or long-term (chronic). Drugs, digital therapeutics, and devices are used to treat insomnia conditions. The main therapy types for insomnia are non-pharmacological therapy and pharmacological therapy. Non-pharmacological interventions (NPI) or non-pharmacological therapies refer to any non-chemical intervention performed on and benefiting the patient, such as light therapy and exercise. The various drug classes include anti-depressants, melatonin antagonist, benzodiazepines, nonbenzodiazepines, orexin antagonist, others. These are administered through various routes of administration such as oral, parenteral, and others, and are distributed through various distribution channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Insomnia Market Growth Forecast?

The insomnia market size is expected to see strong growth in the next few years. It will grow to $7.03 billion in 2030 at a compound annual growth rate (CAGR) of 6.3%. The growth in the forecast period can be attributed to increasing adoption of digital therapeutics, growing demand for safer long-term insomnia treatments, rising geriatric population, increasing mental health awareness, expansion of online and retail pharmacy access. Major trends in the forecast period include growing adoption of non-pharmacological insomnia treatments, rising use of cognitive behavioral therapy for insomnia, increasing preference for personalized sleep management, expanding use of combination therapy approaches, growing awareness of chronic insomnia as a medical condition.

Global Insomnia Market Segmentation

1) By Therapy Type: Non-Pharmacological Therapy, Pharmacological Therapy 2) By Drug Class: Anti-Depressants, Melatonin Antagonist, Benzodiazepines, Nonbenzodiazepines, Orexin Antagonist, Other Drug Classes 3) By Route Of Administration: Oral, Parenteral, Other Route Of Administration 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Non-Pharmacological Therapy: Cognitive Behavioral Therapy For Insomnia (CBT-I), Sleep Hygiene Education, Relaxation Techniques, Stimulus Control Therapy, Sleep Restriction Therapy 2) By Pharmacological Therapy: Prescription Medications, Over-The-Counter, Herbal Supplements

What Is The Driver Of The Insomnia Market?

The increasing prevalence of chronic diseases is expected to propel the growth of insomnia market going forward. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Individuals suffering from chronic diseases, such as cardiovascular disorders, diabetes, and chronic pain conditions, often experience insomnia or other sleep-related issues as a comorbidity. This increased prevalence creates a demand for effective insomnia treatments and management strategies, driving the market for products and services designed to address sleep disorders. For instance, in April 2025, according to the Centers for Disease Control and Prevention, a US-based federal public health agency, 76.4% of US adults representing about 194 million people reported having one or more chronic conditions in 2023, with prevalence at 59.5% among young adults, 78.4% among midlife adults, and 93.0% among older adults. Therefore, the increasing prevalence of chronic diseases is driving the growth of the insomnia industry.

Key Players In The Global Insomnia Market

Major companies operating in the insomnia market are Pfizer Inc., Merck & Co Inc., Sanofi S.A., GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., Viatris Inc., Astellas Pharma Inc., Sun Pharmaceutical Industries Limited, Eisai Co.Ltd., UCLA Health Insomnia Clinic, Jazz Pharmaceuticals PLC, Aurobindo Pharma Limited, Purdue Pharma LP, Cipla Inc., Dr. Reddy's Laboratories Ltd., Zydus Lifesciences Limited, Lupin Limited, Mallinckrodt Pharmaceuticals Plc., Fisher & Paykel Healthcare Corporation Limited, ResMed Inc., Sunovion Pharmaceuticals Inc., Casper Sleep Inc., Biocodex Inc., Vanda Pharmaceuticals Inc., Pernix Therapeutics Holdings Inc., SleepScore Labs, Alpha-Stim, Neurim Pharmaceuticals Ltd., NightWare Inc.

Global Insomnia Market Trends and Insights

Major companies operating in the insomnia market are developing new products such as zaleplon-based insomnia drugs to gain a competitive edge in the market. Zaleplon is a non-benzodiazepine sedative-hypnotic medication used for the short-term treatment of insomnia. For instance, in April 2023, Bukwang Pharm Co Ltd., a South Korea-based pharmaceutical company, launched Zaledeep Cap., the first insomnia treatment in South Korea utilizing zaleplon as its main ingredient. Zaleplon, a non-benzodiazepine drug with FDA approval for treating insomnia, is known for its rapid onset of action, short half-life, and minimal impact on daily activities. With increasing insomnia cases in modern society, the launch of Zaledeep Cap. is expected to provide a new and effective treatment option, aiming to enhance sleep quality and overall well-being for individuals suffering from insomnia.

What Are Latest Mergers And Acquisitions In The Insomnia Market?

In October 2023, dsm-firmenich N.V., a Netherlands-based health and nutrition science company, partnered with Bod Science Pty Ltd to advance the development of one of the world’s first cannabidiol (CBD)-based treatments for insomnia. With this partnership, dsm-firmenich N.V. and Bod Science Pty Ltd aim to progress Bod Science’s investigational cannabinoid therapy for insomnia, utilize dsm-firmenich N.V.’s good manufacturing practice (GMP)-certified pharmaceutical-grade CBD active ingredient to support clinical and regulatory advancement, improve consumer access through Australia’s emerging over-the-counter pathways, and accelerate the development of an innovative sleep-focused therapeutic option. Bod Science Pty Ltd is an Australia-based medical cannabis company that specializes in developing evidence-based CBD formulations for sleep and wellness applications.

Regional Outlook

North America was the largest region in the insomnia market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Insomnia Market?

The insomnia market consists of revenues earned by entities by providing therapies such as light therapy, stimulus control therapy, and relaxation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The insomnia market also includes sales of triazolam, estazolam, temazepam, quazepam, and flurazepam. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Insomnia Market Report 2026?

The insomnia market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the insomnia industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.